Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban
This study has been completed.
Study NCT01436526 Information provided by Bayer
First Received on September 16, 2011. Last Updated on March 21, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Interventions listed in this trial
Rivaroxaban (Xarelto, BAY59-7939)
Sponsors listed in this trial
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers